The FDA has cleared an age-adjusted retinal nerve fibre layer thickness normative database for a proprietary ocular coherence tomography (OCT) device, Spectralis (Heidelberg Engineering).
The FDA has cleared an age-adjusted retinal nerve fibre layer thickness normative database for a proprietary ocular coherence tomography (OCT) device, Spectralis (Heidelberg Engineering).
This new tool has been designed to enable the assessment of glaucoma risk from a patient’s first office visit. Additionally, in combination with proprietary fovea-to-disc alignment software and new posterior pole asymmetry analysis the database aims to increase the power of the OCT instrument for glaucoma risk assessment and progression management.